Visby Medical™, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to ...

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.

Expert Rev Anti Infect Ther. 2011;9(2):237-244.

Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

Testing new antibiotics in India, South Africa or Brazil, where they are needed most, makes scientific sense. But it’ s not without challenges. That's why in India, drug makers like Wockhardt are ...

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, ...

The emergence of Neisseria gonorrhoeae strains resistant to ceftriaxone, the last reliable treatment, poses significant ...

The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a ...

"Getting tested for STIs on a regular basis is an important action that all New Yorkers can take to optimize their health," ...

A decrease in California's sexually transmitted infections (STIs) followed early real-world adoption of doxycycline ...

Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe ...

Aptitude is dedicated to democratizing diagnostics through innovative, accessible testing solutions. The company's Metrix ...